Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Expanded Use of Exparel Nerve Block

Pacira news release; 2018 Apr 6

Pacira Pharmaceuticals, Inc. has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of Exparel (bupivacaine liposome injectable suspension) to include administration via interscalene brachial plexus block to produce postsurgical regional analgesia. With this approval, Exparel is the first long-acting, single-dose nerve block available for patients undergoing upper extremity surgeries, such as total shoulder arthroplasty or rotator cuff repair.

Dosage/administration: Exparel is intended for single-dose administration only. Different formulations of bupivacaine are not bioequivalent even if the milligram strength is the same. It is not possible to convert dosing from other formulations of bupivacaine to Exparel. Exparel should not be diluted with water for injection or other hypotonic solution. The recommended dose of Exparel for local infiltration in adults is up to a maximum dose of 266 mg (20 mL). The recommended dose of Exparel for interscalene brachial plexus nerve block in adults is 133 mg (10 mL).

Adverse reactions: Adverse reactions reported with an incidence ≥10% following Exparel administration via infiltration were nausea, constipation, and vomiting. Adverse reactions reported with an incidence ≥10% following Exparel administration via nerve block were nausea, pyrexia, and constipation.

Citation:

Pacira announces FDA approval of supplemental new drug application for Exparel as a nerve block to produce regional analgesia. [news release]. Parsippany, NJ: Pacira Pharmaceuticals, Inc. April 6, 2018. http://investor.pacira.com/phoenix.zhtml?c=220759&p=irol-newsArticle&ID=2341466. Accessed April 24, 2018.

This Week's Must Reads

PD Global Burden More than Doubles, from 1990-2016, Lancet Neurol; ePub 2018 Oct 1; Dorsey, et al

Disparities Found in Dementia Medication Use for PD, JAMA Neurol, ePub 2018 Oct 1; Mantri, Fullard, et al

Gray Matter Abnormalities in Movement Disorders, Neurology; ePub 2018 Oct 10; Maurer, LaFaver, et al

Periodic Limb Movements in Sleep Increase with Age, Clin Neurophysiol; 2018 Nov; Leary, Moore IV, et al

Cognitive Ability Assessment Tool Proves Effective, Mov Disord; ePub 2018 Oct 10; Holden, Medina, et al

Must Reads in FDA Actions

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3

FDA Approves Epidiolex for Rare Epilepsy Forms, FDA news release: 2018 Jun 25